Opinion|Videos|February 21, 2025
Impact of Patient-Reported Outcomes and Real-World Evidence in CLL and MCL
Panelists discuss how patient-reported outcomes and real-world evidence influence clinical decision-making when selecting Bruton tyrosine kinase (BTK) inhibitors for the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL).
Advertisement
Episodes in this series
- How do patient-reported outcomes and real-world evidence influence your clinical decision-making process when selecting BTK inhibitor therapies for CLL and MCL?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
Prior Authorization Ranked Top Barrier to Health Care Access After Cost
2
FDA Flags Administration Concerns for Aquestive's Noninvasive Epinephrine Film
3
Contributor: The Majority (57.5%) of Commercially Insured Patients Had 1 or More Chronic Conditions in 2024
4
Vutrisiran Improves Survival, Cardiovascular Outcomes Across Age Groups in ATTR-CM
5
